AnaptysBio Revenue and Competitors

Location

$85.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AnaptysBio's estimated annual revenue is currently $122.2M per year.(i)
  • AnaptysBio received $Undisclosed in venture funding in October 2017.
  • AnaptysBio's estimated revenue per employee is $1,018,000
  • AnaptysBio's total funding is $85.9M.
  • AnaptysBio's current valuation is $932.7M. (January 2022)

Employee Data

  • AnaptysBio has 120 Employees.(i)
  • AnaptysBio grew their employee count by 2% last year.

AnaptysBio's People

NameTitleEmail/Phone
1
VP, Corporate DevelopmentReveal Email/Phone
2
SVP CMCReveal Email/Phone
3
VP, Clinical PharmacologyReveal Email/Phone
4
SVP, Clinical OperationsReveal Email/Phone
5
SVP, Head ResearchReveal Email/Phone
6
VP Portfolio and New Product PlanningReveal Email/Phone
7
VP, ControllerReveal Email/Phone
8
VP, Head Immunology ResearchReveal Email/Phone
9
VP Regulatory AffairsReveal Email/Phone
10
VP, Associate General CounselReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is AnaptysBio?

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States. Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP). In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP). Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance. Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene. For more information, visit www.anaptysbio.com.

keywords:Biotechnology

$85.9M

Total Funding

120

Number of Employees

$122.2M

Revenue (est)

2%

Employee Growth %

$932.7M

Valuation

N/A

Accelerator

AnaptysBio News

2022-04-17 - $6.48 Million in Sales Expected for AnaptysBio, Inc. (NASDAQ ...

Equities research analysts expect that AnaptysBio, ... AnaptysBio posted sales of $11.25 million during the same quarter last year,...

2022-04-17 - AnaptysBio (NASDAQ:ANAB) Downgraded to “Sell” at ...

AnaptysBio (NASDAQ:ANAB) Downgraded to “Sell” at StockNews.com. Posted by admin on Apr 15th, 2022. Share on Twitter Share on Facebook Share on LinkedIn...

2022-04-17 - Global Antibody Library Technology Market 2022 Upcoming ...

AnaptysBio Inc; MorphoSys AG; XOMA Corporation; Abzena Plc; AvantGen Inc; Adimab LLC; AbCheck s.r.o.; Philogen S.p. A.; Creative-Biolabs...

2021-10-25 - AnaptysBio : Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard

AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty Partners Sagard to receive AnaptysBio’s 8% royalty on annual global net sales of JEMPERLI (dostarlimab-gxly) below $1 billion, plus certain future regulatory and commercial sales milestones, while AnaptysBio r ...

2017-01-27 - AnaptysBio's Upsized IPO Raises $75 Million

San Diego biotech AnaptysBio ended up raising $75 million in an upsized initial public offering Jan. 26, making it the first biotech in the country to go public this year. The company, which initially priced its IPO at $60 million on Jan. 23, sold 5 million shares (about 1 million more than exp ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25.2M1205%N/A
#2
$25.2M1205%N/A
#3
$32.4M12041%N/A
#4
$32.4M12011%N/A
#5
$16.9M12115%$60.3M

AnaptysBio Funding

DateAmountRoundLead InvestorsReference
2007-11-09$33.9MBNovo A/SArticle
2015-07-16$40.0MDBVF Partners L.PArticle
2017-10-12$UndisclosedUndisclosedCredit SuisseArticle